News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dicerna Pharmaceuticals (DRNA) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)


4/21/2014 9:45:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that it granted stock options to Pankaj Bhargava, M.D., the Company’s chief medical officer, on April 16, 2014, including a stock option to purchase 246,406 shares of common stock of the Company outside of the Company’s stockholder approved equity incentive plan. The grant of this stock option was approved by the compensation committee of the board of directors on April 16, 2014 as an inducement material to Dr. Bhargava entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES